There are five distinct hormonal phases that the female body goes through that create a specific biochemical environment affecting women in the different stages of their life- juvenile, puberty, reproduction, pregnancy & post-reproduction.
The passage from the reproductive to the post-reproduction stage creates a dramatic period that greatly affect women’s quality of life and health for more than a quarter of their life span. The post-reproduction stage has very dominant characteristics and starts in the peri-menopause stage where the hormonal imbalance creates great turmoil, turning into menopause and post-menopause.
From our experience returning hormonal balance through the use of HT, has provided advantages. In practice however, the clinical and psychological reservations, bring the important supporting treatment to a hard-pressed corner. This situation emphasizes the importance of an additional solution that can provide a treatment that can support women in the long haul, which is critical for healthy aging and better quality of life.
Biomimetics or biomimicry is an approach to innovation that seeks sustainable solutions to human challenges by emulating nature’s time-tested patterns and strategies. Based on this approach, a unique compound acting as a Selective Estrogen Receptor Modulator (SERM), from botanical origin, was developed.
Estrogen Receptors (ERs) our found in most of the female body’s tissues, thus, the decline in the production of estrogen at menopause, creates a great imbalance that affects all the organs. In all hormonal phases, a specific biochemical environment, expressed through the bondage with different co-activators, triggers a response according to the age and circumstantial needs of women. The bondage of estrogen to a co-activator acts as a catalyst in the evolvement of the response based on the body’s needs. Contrary to HT, the mimicry of a SERM is selective, promoting an agonistic response only in desired tissues while mimicking the attachment of E2 to a co-repressor in the sensitive tissues of the breast and uterus, providing an antagonistic bond of the ER.
A beautiful example of bio-mimicry is a molecule called DT56a.The scientific backup of DT56a, including a head to head study vs. HT, has shown it to offer women the same efficacy as HT in relieving symptoms and detaining post-menopausal diseases, while providing a safety profile that can put at rest all reservations to treatment. This development suggests a great first line treatment for the management of menopause, providing the efficacy needed for the management of post-menopause health challenges, without adding risk factors.